American Journal of Veterinary Research 2000-08-01

Pharmacokinetics of erythromycin estolate and erythromycin phosphate after intragastric administration to healthy foals.

J Lakritz, W D Wilson, A E Marsh, J E Mihalyi

Index: Am. J. Vet. Res. 61(8) , 914-9, (2000)

Full Text: HTML

Abstract

To determine pharmacokinetics and plasma concentrations of erythromycin and related compounds after intragastric administration of erythromycin phosphate and erythromycin estolate to healthy foals.11 healthy 2- to 6-month-old foals.Food was withheld from foals overnight before intragastric administration of erythromycin estolate (25 mg/kg of body weight; n = 8) and erythromycin phosphate (25 mg/kg; 7). Four foals received both drugs with 2 weeks between treatments. Plasma erythromycin concentrations were determined at various times after drug administration by use of high-performance liquid chromatography. Maximum plasma peak concentrations, time to maximum concentrations, area under plasma concentration versus time curves, half-life of elimination, and mean residence times were determined from concentration versus time curves.Maximum peak concentration of erythromycin A after administration of erythromycin phosphate was significantly greater than after administration of erythromycin estolate (2.9 +/- 1.1 microg/ml vs 1.0 +/- 0.82 microg/ml). Time to maximum concentration was shorter after administration of erythromycin phosphate than after erythromycin estolate (0.71 +/- 0.29 hours vs 1.7 +/- 1.2 hours). Concentrations of anhydroerythromycin A were significantly less 1 and 3 hours after administration of erythromycin estolate than after administration of erythromycin phosphate.Plasma concentrations of erythromycin A remained > 0.25 microg/ml (reported minimum inhibitory concentration for Rhodococcus equi) for at least 4 hours after intragastric administration of erythromycin phosphate or erythromycin estolate, suggesting that the recommended dosage for either formulation (25 mg/kg, q 6 h) should be adequate for treatment of R equi infections in foals.


Related Compounds

Related Articles:

Protective effect of Livex, a herbal formulation against erythromycin estolate induced hepatotoxicity in rats.

1998-01-01

[J. Ethnopharmacol. 57(3) , 161-7, (1997)]

Preparation and characterization of biodegradable poly(l-lactide)/poly(ethylene glycol) microcapsules containing erythromycin by emulsion solvent evaporation technique.

2004-03-15

[J. Colloid. Interface Sci. 271(2) , 336-41, (2004)]

Five days of erythromycin estolate versus ten days of penicillin V in the treatment of group A streptococcal tonsillopharyngitis in children. Pharyngitis Study Group.

1996-09-01

[Eur. J. Clin. Microbiol. Infect. Dis. 15(9) , 712-7, (1996)]

Pharmacokinetics of erythromycin after the administration of intravenous and various oral dosage forms to dogs.

2008-12-01

[J. Vet. Pharmacol. Ther. 31(6) , 496-500, (2008)]

Multicenter, randomized, double-blind comparison of erythromycin estolate versus amoxicillin for the treatment of acute otitis media in children. AOM Study Group.

1998-07-01

[Eur. J. Clin. Microbiol. Infect. Dis. 17(7) , 470-8, (1998)]

More Articles...